Skip to Content
Rating as of

Morningstar’s Analysis

Currency in AUD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Company Profile

Business Description

Acrux Ltd is an Australian pharmaceutical company dedicated to developing and commercializing generic transdermal and topical prescription pharmaceuticals. Its products include Testosterone Solution, Estradiol MDTS and others. It also has some of its products under the pipeline. Geographically, it has a presence in Australia; Germany; United States, and other countries. It generates maximum revenue from the Lenzetto product.

103-113 Stanley Street, West Melbourne
Melbourne, VIC, 3003, Australia
T +61 383790100
Sector Healthcare
Industry Biotechnology
Most Recent Earnings
Fiscal Year End Jun 30, 2021
Stock Type
Employees 36